The US Supreme Court declined to hear a case that asked whether patent holders can collect royalties after their patents expire, rejecting Atrium Medical Corp.'s request in a licensing fight with
The justices on Monday rejected Atrium’s petition for a writ of certiorari, allowing the US Court of Appeals for the Ninth Circuit’s August 2024 ruling to stand. That decision upheld Bard’s right to enforce a $15 million-a-year minimum payment clause in a license agreement after its US patent on vascular stents expired. The court noted that Justice Samuel Alito didn’t participate in the decision to deny ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.
